MA27182A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar. - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Info

Publication number
MA27182A1
MA27182A1 MA27840A MA27840A MA27182A1 MA 27182 A1 MA27182 A1 MA 27182A1 MA 27840 A MA27840 A MA 27840A MA 27840 A MA27840 A MA 27840A MA 27182 A1 MA27182 A1 MA 27182A1
Authority
MA
Morocco
Prior art keywords
ppar
activity
compounds
thiazole
modulate
Prior art date
Application number
MA27840A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Chitase Lee
Noe Ouano Erasga
Andrew George Geyer
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27182A1 publication Critical patent/MA27182A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite: WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 7 Mars 2002 60/362,400 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de thiazole et d'oxazole qui modulent l'activité de PPAR La présente invention décrit des composés qui modifient l'activité de PPAR. La présente invention décrit également des sels pharmaceutiquement acceptables des composés, des compositions pharmaceutiquement acceptables comprenant les composés ou leurs sels, et des méthodes pour leur utilisation comme agents thérapeutiques pour le traitement ou la prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention décrit également un procédé pour la préparation des composés décrits.
MA27840A 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar. MA27182A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
MA27182A1 true MA27182A1 (fr) 2005-01-03

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27840A MA27182A1 (fr) 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Country Status (29)

Country Link
US (1) US6833380B2 (fr)
EP (1) EP1485091A1 (fr)
JP (1) JP2005524665A (fr)
KR (1) KR20040091694A (fr)
CN (1) CN1638768A (fr)
AP (1) AP2004003123A0 (fr)
AR (1) AR038883A1 (fr)
AU (1) AU2003207891A1 (fr)
BR (1) BR0308221A (fr)
CA (1) CA2476580A1 (fr)
CO (1) CO5601013A2 (fr)
EA (1) EA200401160A1 (fr)
EC (1) ECSP045275A (fr)
GT (1) GT200300053A (fr)
HR (1) HRP20040810A2 (fr)
IL (1) IL163768A0 (fr)
IS (1) IS7399A (fr)
MA (1) MA27182A1 (fr)
MX (1) MXPA04008624A (fr)
NO (1) NO20044245L (fr)
OA (1) OA12781A (fr)
PA (1) PA8568701A1 (fr)
PE (1) PE20031010A1 (fr)
PL (1) PL372971A1 (fr)
TN (1) TNSN04167A1 (fr)
TW (1) TW200400027A (fr)
UY (1) UY27704A1 (fr)
WO (1) WO2003074052A1 (fr)
ZA (1) ZA200406491B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
EP1745014B1 (fr) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Nouveaux composes, leur preparation et leur utilisation
WO2005115384A2 (fr) * 2004-05-25 2005-12-08 Metabolex, Inc. Triazoles substitués bicyliques comme modulateurs de ppar et méthodes de préparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
EA201101084A1 (ru) 2005-12-22 2012-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
CA2696948C (fr) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1, 4'] bipyridinyl-2'-ones 1', 3'-disusbstituees
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
EP2220083B1 (fr) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Dérivés d'imidazo[1,2-a]pyridines et leur utilisation en tant que modulateurs allostériques positifs de récepteurs mglur2
CA2735764C (fr) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derives de 3-azabicyclo[3.1.0]hexyle comme modulateurs des recepteurs metabotropiques du glutamate
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
EP2643320B1 (fr) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. Dérivés de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2815002C (fr) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. Derives 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
IL128600A0 (en) 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
CA2418104A1 (fr) 2000-08-23 2002-02-28 Eli Lilly And Company Derives d'acide oxazolyl-arylpropionique et leur utilisation comme agonistes des ppar
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002050047A1 (fr) 2000-12-20 2002-06-27 Glaxo Group Limited Oxazoles et thiazoles substitues utiles en tant qu'agonistes de hppar alpha
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
KR100874677B1 (ko) 2001-05-29 2008-12-18 교토 야쿠힝 고교 가부시키가이샤 신규 복소환 유도체 및 그 의약 용도
EA200400011A1 (ru) 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
DE60226441D1 (de) 2001-06-18 2008-06-19 Ono Pharmaceutical Co Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6869975B2 (en) 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
WO2003074052A1 (fr) 2003-09-12
ECSP045275A (es) 2004-10-26
GT200300053A (es) 2003-10-10
AP2004003123A0 (en) 2004-09-30
PA8568701A1 (es) 2003-11-12
TNSN04167A1 (fr) 2007-03-12
CA2476580A1 (fr) 2003-09-12
EA200401160A1 (ru) 2005-02-24
KR20040091694A (ko) 2004-10-28
JP2005524665A (ja) 2005-08-18
IL163768A0 (en) 2005-12-18
HRP20040810A2 (en) 2004-12-31
OA12781A (en) 2006-07-07
CN1638768A (zh) 2005-07-13
PL372971A1 (en) 2005-08-08
EP1485091A1 (fr) 2004-12-15
TW200400027A (en) 2004-01-01
UY27704A1 (es) 2003-10-31
CO5601013A2 (es) 2006-01-31
AU2003207891A1 (en) 2003-09-16
US20030207916A1 (en) 2003-11-06
AR038883A1 (es) 2005-02-02
NO20044245L (no) 2004-10-06
BR0308221A (pt) 2005-01-04
MXPA04008624A (es) 2004-12-06
ZA200406491B (en) 2006-05-31
US6833380B2 (en) 2004-12-21
IS7399A (is) 2004-08-12
PE20031010A1 (es) 2003-12-12

Similar Documents

Publication Publication Date Title
MA27181A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
TNSN04167A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA27568A1 (fr) Derives de pyrrolopyrimidine
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
MA30231B1 (fr) Derives de benzamides et d'heteroarenes
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA27135A1 (fr) Agents antidiabetiques oraux
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
IL152337A0 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
SE9903997D0 (sv) New compounds
MA26953A1 (fr) Derives de pipérazine pontés.